Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Prostate. 2011 Jul 14;72(5):514–522. doi: 10.1002/pros.21453

Figure 3. Recovery of prostate-specific CD8 T cell function in an antigen-free environment.

Figure 3

(3A) CD8 T cell function assayed via in vivo CTL assay. Top Row: negative control, unvaccinated, nontransgenic hosts. Second Row: Vaccination of TCR transgenic (C4) or double transgenic (C4 x ProTRAMP) hosts.

(3B) Adoptive transfer of naïve Clone 4 (C4) or C4 from tumor bearing (C4 × ProTRAMP) donors into nontransgenic (NT) hosts, in both cases followed by vaccination. In all studies left peak represents antigen loaded targets, right peak unloaded control. N = 3–5 animals / group, representative of 3 independent experiments.

(3C) Quantification of CTL function post-transfer. Leftmost bar represents unvaccinated NT hosts (negative control). N = 3–5 / group, repeated × 3.

(3D) Quantification of cytokine production after vaccination of C4 or C4 × ProTRAMP (tumor bearing hosts. Leftmost bar (positive control) represents Clone 4 cells adoptively transferred into nontransgenic (NT) hosts. Remaining bars from in situ vaccination of animals indicated. Pooled data from 2 independent studies with a minimum of 3 animals / group.